NVO vs. NOV.DE

In the year-to-date period, NVO achieves a -26.02% return, which is significantly higher than NOV.DE's -33.28% return. Over the past 10 years, NVO has underperformed NOV.DE with an annualized return of 10.45%, while NOV.DE has yielded a comparatively higher 12.82% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Novo Nordisk A/S (NVO) and Novo Nordisk A/S (NOV.DE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current NVO Sharpe Ratio is -1.18, which is comparable to the NOV.DE Sharpe Ratio of -1.24. The chart below compares the historical Sharpe Ratios of NVO and NOV.DE, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

NVO's dividend yield for the trailing twelve months is around 2.58%, more than NOV.DE's 0.37% yield.

The maximum NVO drawdown since its inception was -70.96%, which is greater than NOV.DE's maximum drawdown of -61.67%. Use the drawdown chart below to compare losses from any high point for NVO and NOV.DE. For additional features, visit the drawdowns tool.

Novo Nordisk A/S (NVO) has a higher volatility of 16.91% compared to Novo Nordisk A/S (NOV.DE) at 15.92%. This indicates that NVO's price experiences larger fluctuations and is considered to be riskier than NOV.DE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Novo Nordisk A/S and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.